Pharmacokinetics of venlafaxine extended release 75mg and desvenlafaxine 50mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study

Clinical Drug Investigation

Volumn 31, Issue 3, 2011, Pages 155-167

  Nichols, Alice I ^a   Focht, Kristen ^a   Jiang, Qin ^a   Preskorn, Sheldon H ^b   Kane, Cecelia P ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Cytochrome P450; Depression; Desvenlafaxine; pharmacokinetics; Research and development; Venlafaxine

Indexed keywords

CYTOCHROME P450 2D6; DESVENLAFAXINE; DRUG METABOLITE; VENLAFAXINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG RELEASE; FEMALE; GENOTYPE; GEOMETRY; HOSPITAL PATIENT; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 79751517514     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586630-000000000-00000     Document Type: Article

References (26)

1. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 Jan; 369 (1): 23-37 (Pubitemid 38161221)
2. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part I). J Psychiatr Pract 2003 Mar; 9 (2): 150-8 (Pubitemid 36717613)
3. de Leon J,Armstrong SC,CozzaKL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 andCYP450 2C19. Psychosomatics 2006 Jan; 47 (1): 75-85 (Pubitemid 43017126)
4. Mulder H, Herder A, Wilmink FW, et al. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006 Feb; 15 (2): 107-14
5. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006 Aug; 318 (2): 657-65 (Pubitemid 44061240)
6. Howell SR, Husbands GE, Scatina JA, et al. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993 Apr; 23 (4): 349-59 (Pubitemid 23166409)
7. Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009 Feb; 29 (1): 39-43
8. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999 Aug; 9 (4): 435-43 (Pubitemid 29419562)
9. Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. CYP2D6 phenotype predicts antidepressant efficacy of venlafaxine. J Clin Psychiatry doi:10.4088/JCP. 08m04773blu. Epub
10. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006 Oct; 31 (5): 493-502 (Pubitemid 44337299)
11. Wijnen PA, Limantoro I, Drent M, et al. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann Clin Biochem 2009 Nov; 46 (Pt 6): 527-30
12. Pristiq [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals Inc.; 2008
13. Nichols AI, Lobello K, Guico-Pabia CJ, et al. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 2009 Aug; 29 (4): 383-6
14. Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004; 4 (16): 1733-44 (Pubitemid 39654459)
15. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997 Feb; 60 (2): 284-95 (Pubitemid 27058401)
16. Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009; 14 (4): 183-95
17. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9 (5): 442-73 (Pubitemid 38903502)
18. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693
19. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 Dec; 23 (36): 9312-8
20. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010 Mar; 28 (8): 1287-93
21. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009 Oct; 302 (13): 1429-36
22. Kuderer NM, Peppercorn J. CYP2D6 testing in breast cancer: ready for prime time? Oncology (Williston Park) 2009 Dec; 23 (14): 1223-32
23. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004 May; 75 (5): 386-93 (Pubitemid 38534559)
24. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008 Apr; 65 (4): 558-64 (Pubitemid 351365130)
25. Mulder H, Wilmink FW, Beumer TL, et al. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol 2005 Apr; 25 (2): 188-91 (Pubitemid 40395102)
26. Zourkova A, Ceskova E, Hadasova E, et al. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007 Jul; 33 (4): 343-55 (Pubitemid 46868495)